

REMARKS

Status of the Claims

Claims as Filed

Claims 1 to 9 are pending in the specification as filed.

Claims canceled, added and amended

In the instant preliminary amendment, Applicants canceled claims 6 and 7, amended claims 1 to 5 and 8, and added new claims 10 and 11. Thus, after entry of the instant amendment, claims 1 to 5 and 8 to 11 will be pending.

Support for the Claim Amendments

The specification sets forth an extensive description of the invention in the new and amended claims.

CONCLUSION

In view of the foregoing remarks and the instant amendment, it is believed that the all claims pending in this application (after entry of the instant amendment) are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.


If any additional necessary fee is required, the Commissioner is authorized to deduct such a fee from the undersigned's Deposit Account No. 06-1050. Please credit any overpayments to the above-noted Deposit Account.

2001-08-31 16:50:00

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (858) 678-5070.

Date: Aug 31, 2001

Respectfully submitted,


Gregory P. Einhorn
Reg. No. 38,440

Fish & Richardson P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, California 92122
Telephone: (858) 678-5070
Facsimile: (858) 678-5099

10131279.doc

10131279.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE




Applicant : Nishino, N., et al. Art Unit : to be assigned
Serial No. : to be assigned Examiner : to be assigned
Filed : August 31, 2001
Title : NOVEL CYCLIC TETRAPEPTIDE DERIVATIVES AND
 PHARMACEUTICAL USES THEREOF

In The Claims:


Claims 6 and 7 have been canceled.

Claim 1 has been amended as follows:

1. (Amended) A cyclic tetrapeptide derivative comprising a [represented by the following] general formula selected from the group consisting of (I), (I'), (I''), (I''') [or] and a pharmaceutically acceptable salt thereof:



FILED "2001" 2001



wherein each of R₁₁, R₁₂, R₂₁ and R₂₂ independently denotes hydrogen, a linear C₁-C₆-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached, or a branched C₃-C₆-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached; and

each of R₁, R₂ and R₃ independently denotes a linear C₁-C₅-alkylene group which may have a C₁-C₆ side chain, in which the side chain may form a condensed ring structure on the alkylene chain;

provided that at least one of R₁₁, R₁₂, R₂₁ and R₂₂ in general formula (I''') is a cyclohexyl methyl group.

2. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I), or a pharmaceutically acceptable salt thereof.

3. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I'), or a pharmaceutically acceptable salt thereof.

4. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I''), or a pharmaceutically acceptable salt thereof.

5. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I'''), or a pharmaceutically acceptable salt thereof.

8. (Amended) A pharmaceutical composition comprising a [the] cyclic tetrapeptide derivative or a pharmaceutically acceptable salt thereof [according to any one of claims] as set forth in claim 1 [to 5 as an active ingredient].

The following new claims have been added:

10. A method of inhibiting a histone deacetylase comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or a pharmaceutically acceptable salt thereof as set forth in claim 1, thereby inhibiting a histone deacetylase inhibitor.

11. A method of promoting an expression of an MHC class I molecule comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or pharmaceutically acceptable salt thereof as set forth in claim 1, thereby promoting an expression of an MHC class I molecule.